FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
The historical rank and industry rank for Profound Medical's FCF Yield % or its related term are showing as below:
TSX:PRN'
s FCF Yield % Range Over the Past 10 Years
Min: -34.38 Med: -13.62 Max: -3.91
Current: -13.92
During the past 12 years, the highest FCF Yield % of Profound Medical was -3.91%. The lowest was -34.38%. And the median was -13.62%.
TSX:PRN's FCF Yield % is ranked worse than 78.27% of 856
companies
in the Medical Devices & Instruments industry
Industry Median: -0.39
vs TSX:PRN: -13.92
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Profound Medical FCF Yield % Related Terms
Profound Medical FCF Yield % Historical Data
* Premium members only.
The historical data trend for Profound Medical's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Profound Medical's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Profound Medical FCF Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Profound Medical's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Profound Medical's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Profound Medical (TSX:PRN) has a FCF Yield % of -13.92 as of Jul. 07, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Profound Medical and its competitors. According to the industry distribution chart, Profound Medical ranks #670 out of 856 companies in the Medical Devices & Instruments industry, placing it in the top 78.3%.
Is Profound Medical's FCF Yield % too high?
Profound Medical's current FCF Yield % is -13.92. Based on the distribution chart, Profound Medical ranks #670 out of 856 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Profound Medical has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Profound Medical's FCF Yield % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Profound Medical ranks #670 out of 856 companies for FCF Yield %. This places Profound Medical in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Medical Devices & Instruments company?
A good FCF Yield % depends on the Medical Devices & Instruments industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Profound Medical and its competitors. Profound Medical's current FCF Yield % is -13.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Profound Medical stock overvalued right now?
Based on GuruFocus' analysis, Profound Medical (TSX:PRN) is currently considered Possible Value Trap. The stock's GF Value™ is C$20.37, compared to a current price of C$10.46 — trading 48.6% below its estimated fair value. The current FCF Yield % is -13.92. Profound Medical's overall GF Score™ is 68/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Profound Medical (TSX:PRN), the current FCF Yield % is -13.92 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Profound Medical (TSX:PRN) Overvalued in 2026?
Based on GuruFocus' analysis, Profound Medical stock appears to be undervalued.
The current stock price of C$10.46 is trading 48.6% below its estimated GF Value™ of C$20.37.
GuruFocus considers Profound Medical to be Possible Value Trap.
Key valuation signals for TSX:PRN:
FCF Yield %: -13.92
GF Value™: C$20.37 vs. price of C$10.46 (48.6% below fair value)
No single metric tells the full story. See the TSX:PRN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.
68GF Score
Get the complete analysis for TSX:PRN
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:PRN has been successfully added to your 
